Sacha Schermerhorn theorizes that tau fibrils cause neurodegeneration in Alzheimer's not by their presence, but by sequestering essential proteins, leading to a loss of function.

Sacha Schermerhorn expects the clinical trial readout for Biogen's BIIB080 to be delayed from its slated May date to Q4 of this year due to recruitment difficulties.

Sacha Schermerhorn predicts that BIIB080, an intrathecally delivered tau ASO from Biogen and Ionis, will be the most efficacious drug for Alzheimer's to date.

Approximately half of all research funding for Alzheimer's disease has been spent on the amyloid cascade hypothesis.

Trontinimab is an antibody therapeutic that hijacks the transferrin receptor to increase its transport across the blood-brain barrier, resulting in the best amyloid clearance efficacy seen to date.

Pfizer acquired Biohaven for $11.6 billion after Biohaven successfully developed Rimegepant, a migraine drug it had licensed from Bristol Myers Squibb.

Sacha Schermerhorn believes that fine-tuning will define the next decade of AI development.

An initial epidemiological study found that people taking sildenafil (Viagra) were 69% less likely to develop Alzheimer's, though follow-on studies were unable to reproduce this finding.

A 1991 study by Simon LeVay published in Science found that the third interstitial nucleus of the anterior hypothalamus is 2.8 times larger in heterosexual males than in homosexual males and women.

Babylon Bio was founded with the mission of finding a cure for Alzheimer's disease.

Babylon Bio is collaborating with OpenAI to fine-tune models that can predict clinical trial outcomes, using the binary success or failure of trials as a loss function to train the models on biologica...

The FDA advisory committee for Biogen's Aducanumab, consisting of 14 members, unanimously rejected the drug's approval, yet it was still submitted for approval.

The biomarker p-tau217, a fragment of tau tangles, is the single most predictive marker for when an individual will develop the cognitive impairment phase of Alzheimer's disease.

Biomarker data indicates that amyloid plaques begin to deposit in the brain 20 to 30 years before the onset of Alzheimer's symptoms.

Only 0.1% of a monoclonal antibody therapeutic administered to a patient will cross the blood-brain barrier and enter the brain.

Babylon Bio's strategy involves acquiring and developing shelved pharmaceutical assets that could generate exits in the low nine-figure range to self-finance its primary Alzheimer's research.

The Alzheimer's drug Aducanumab reduced amyloid PET imaging signals by approximately 76% but showed no impact on patient cognition.

A study in Wales found that individuals who received the shingles vaccine were 20% less likely to develop Alzheimer's disease or all-cause dementia within a seven-year period.